Retinal Ischemic Perivascular Lesions (RIPLs) as Potential Biomarkers for Systemic Vascular Diseases: A Narrative Review of the Literature
Ophthalmology and Therapy · 2025-06 · 14 (6) · 1183-1197
DOI: 10.1007/s40123-025-01148-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ophthalmology and Therapy, online erschienen am 28.04.2025. Verfasst von Celeste Limoli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London, UK. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Retinal ischemic perivascular lesions (RIPLs) are characteristic focal thinning of the inner nuclear layer, with an upward expansion of the outer nuclear layer identified by spectral domain optical coherence tomography (SD-OCT), causing a focal irregular appearance of the middle retina. RIPLs result from retinal hypoperfusion in the deep capillary plexus, as a legacy of paracentral acute middle maculopathy, representing permanent anatomical markers of prior ischemic events. Although frequently found incidentally during routine eye examinations, RIPLs may provide insights into subclinical vascular damage that underpins various cardio- and cerebrovascular diseases. The aim of this narrative review is to summarize the relationships of RIPLs with retinal and systemic vascular diseases, including arterial hypertension, coronary artery disease, carotid artery stenosis, atrial fibrillation, stroke, sickle cell disease, and diabetes mellitus. Cardiovascular and metabolic diseases, which are the leading causes of morbidity and mortality worldwide, often remain asymptomatic for years despite early structural changes until severe adverse events occur. Noninvasive retinal biomarkers such as RIPLs, which are readily and noninvasively detected through SD-OCT scans, could help in the early detection and stratification of patients at risk for cardiovascular diseases, facilitate timely medical interventions and lifestyle changes, and ultimately improve disease prevention in a "personalized medicine" approach. While further research is needed to establish the prevalence of RIPLs in the general population and their full clinical significance, advances in ophthalmic imaging technologies combined with rapid progress in artificial intelligence applications in medical research could accelerate the development of RIPLs in retinal imaging-based oculomics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London, UK.
- UCL Institute of Ophthalmology, London, UK.
- Department of Ophthalmology, Tanta University, Tanta, Egypt.
- Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London, UK. josef.huemer1@nhs.net.
- UCL Institute of Ophthalmology, London, UK. josef.huemer1@nhs.net.
- Department of Ophthalmology and Optometry, Kepler University Hospital, Linz, Austria. josef.huemer1@nhs.net.
Zitieren
APA
Limoli, C., Khalid, H., Wagner, S. K., & Huemer, J. (2025). Retinal Ischemic Perivascular Lesions (RIPLs) as Potential Biomarkers for Systemic Vascular Diseases: A Narrative Review of the Literature. Ophthalmology and Therapy, 14(6), 1183-1197. https://doi.org/10.1007/s40123-025-01148-5
Vancouver
Limoli C, Khalid H, Wagner SK, Huemer J. Retinal Ischemic Perivascular Lesions (RIPLs) as Potential Biomarkers for Systemic Vascular Diseases: A Narrative Review of the Literature. Ophthalmology and Therapy. 2025;14(6):1183-1197. doi:10.1007/s40123-025-01148-5
BibTeX
@article{Limoli2025,
author = {Limoli, Celeste and Khalid, Hagar and Wagner, Siegfried K and Huemer, Josef},
title = {Retinal Ischemic Perivascular Lesions (RIPLs) as Potential Biomarkers for Systemic Vascular Diseases: A Narrative Review of the Literature},
journal = {Ophthalmology and Therapy},
year = {2025},
volume = {14},
number = {6},
pages = {1183--1197},
doi = {10.1007/s40123-025-01148-5}
}
EUVIMED